Patent System to Catch Up with Pharmaceutical Industry Expansion
The pharmaceutical industry in China has been expanding in recent years as the government strives to invent its own drugs and brands. However, the prevalence of counterfeit and generic drugs still remains a significant IP issue. The patent system needs further development before it will be able to properly protect patent holders.
Issue: June 2008
Keywords (click to search):
The execution of Zheng Xiaoyu for corruption and
dereliction of duty made headlines last year. As former
director of Chinese watchdog the State Food and Drug
Administration (SFDA), Zheng's death sentence reflects the PRC
government's determination to protect consumers. For the
pharmaceutical industry, the execution represented a step in
the right direction. This sector has been widely criticized due
to the prevalence of fake drugs and the lack of intellectual
property (IP) protection from the government. The 2003 SARS
attack, worldwide anger over deaths caused by the exportation
of contaminated food and fake drugs, and Zheng's approval of
unsafe drugs in violation of new rules all exposed China's lack
of enforcement in the health care system. The Zheng scandal
alerted the government to the need to reform the nation's
pharmaceutical image by promulgating new measures and
regulations. At the opening of the National People's Congress
Premier Wen Jiabao emphasized the...
Register with China Law & Practice to unlock our premium content for the next 14 days.
**Full text translations are only available for individual purchase or as part of a subscription.**